FDA Warns Siemens On Marketing Claims For Syngo Arterial Health Package
This article was originally published in The Gray Sheet
Executive Summary
FDA's recent warning letter to Siemens Medical is an example of the agency's recent crackdown on unapproved marketing and promotional claims by device manufacturers
You may also be interested in...
FDA Surveillance Of Ads, Promotional Materials To Increase
FDA says it is stepping up surveillance of advertising and promotional materials for medical devices
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.